A Randomized, Open-label Study of the Safety and Efficacy of Multi- Vessel Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With Cardiomyopathy Secondary to Duchenne Muscular Dystrophy

Trial Profile

A Randomized, Open-label Study of the Safety and Efficacy of Multi- Vessel Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With Cardiomyopathy Secondary to Duchenne Muscular Dystrophy

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs CAP-1002 (Primary)
  • Indications Cardiomyopathies; Duchenne muscular dystrophy
  • Focus Adverse reactions
  • Acronyms HOPE-1; HOPE-DUCHENNE
  • Sponsors Capricor
  • Most Recent Events

    • 04 Oct 2017 First six months of follow-up data presented in Capricor Therapeutics media release.
    • 04 Oct 2017 First six months of follow-up data presented at the 22nd Annual International Congress of the World Muscle Society, according to a Capricor Therapeutics media release.
    • 18 Sep 2017 According to a Capricor Therapeutics media release, this trial is funded in part by the California Institute for Regenerative Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top